It has been previously suggested that oxytocin (Oxt) may act as a natural antipsychotic. To test this hypothesis, we investigated whether disruption of the oxytocin gene (OxtÀ/À) made mice more susceptible to the psychosis-related effects of amphetamine (Amp), apomorphine (Apo) and phencyclidine (PCP). We examined drug-induced changes in the prepulse inhibition (PPI) of the startle reflex, a measure of sensorimotor gating deficits characteristic of several psychiatric and neurological disorders, including schizophrenia. We found that treatment with Amp, Apo and PCP all had effects on PPI. However, in OxtÀ/À mice, but not Oxt þ / þ mice, PCP treatment resulted in large PPI deficits. As PCP is a noncompetitive N-methyl-D-aspartic acid receptor antagonist, these findings suggest that the absence of Oxt alters the glutamatergic component of the PPI.
Introduction
Several psychiatric and neurological disorders, including schizophrenia, [1] [2] [3] [4] [5] [6] [7] [8] obsessive compulsive disorder, 9, 10 Huntington's disease 11 and Tourette's syndrome, [12] [13] [14] show marked deficits in information processing and filtering of stimuli. Specifically, sensorimotor gating, which involves the inhibition of a motor response by the presence of a sensory event, is impaired in these individuals. Across animal species, including humans, sensorimotor gating can be assessed using measures of prepulse inhibition (PPI) of the startle reflex. In PPI, a weak sensory event (prepulse) inhibits the reflexive motor response to an intense, quickly following, sensory stimulus. Disruptions in PPI are reflective of abnormalities within the cortico-striato-pallido-pontine (CSPP) circuitry, which includes areas such as the nucleus accumbens, the dorsal hippocampus and the basolateral amygdala. [15] [16] [17] So, while disrupted PPI is a sign of several disorders, it not predictive of a specific disorder; rather, it is the result of underlying damage or abnormality to the CSPP circuitry.
Currently, three neurotransmitter systems, the dopaminergic, serotonergic and glutamatergic, have been implicated in the regulation of PPI. Pharmacological manipulation of these systems models PPI deficits and is used to examine the critical circuits involved in PPI as well as to test the efficacy and action of antipsychotic medications. Unfortunately, none of these models offers a complete picture of the regulation of PPI, indicative of the complexity of disrupted PPI in psychiatric and neurological disorders. One issue is that there are likely differences in the neurochemistry underlying PPI deficits across disorders. Another is that other neurotransmitters and neuromodulators are interacting with these three main systems to affect PPI. One neurohormone thought to interact with some, if not all, of these systems is oxytocin (Oxt).
Oxt is a 9-amino-acid neuropeptide made primarily in magnocellular neurons of the paraventricular nucleus (PVN) and supraoptic nucleus (SON) and secreted into the peripheral blood stream from the posterior pituitary. Within the brain, Oxt that is not routed to the pituitary is synthesized by and transported from smaller, parvocellular neurons located in PVN and elsewhere. While peripheral Oxt release is important during parturition and lactation, central Oxt release can affect maternal behavior and learning and memory. [18] [19] [20] [21] [22] In patients diagnosed with either schizophrenia or obsessive compulsive disorder, there have been reports of elevated Oxt baseline concentrations in cerebral spinal fluid (CSF) in some, 23, 24 but not all, 25 studies. Rats treated with antipsychotics have elevated Oxt secretion, 26 suggesting that endogenous Oxt may be important for the effects of antipsychotic drugs. Also in rats, pharma-cologically disrupted PPI can be restored with Oxt administration. 27 Consequently, it has been hypothesized that Oxt may act as an endogenous antipsychotic. 27, 28 In 'normal' animals, PPI is disrupted by the administration of drugs such as apomorphine (Apo) that acts as an agonist at D1 and D2 family dopamine receptors and amphetamine (Amp) that releases and inhibits reuptake of dopamine, 29, 30 as well as the noncompetitive N-methyl-D-aspartic acid (NMDA)/ glutamate receptor antagonist phencyclidine (PCP). 29, 31 The availability of Oxt knockout (À/À) mice provided an opportunity to assess, in the PPI model, the hypothesis that Oxt can act as a 'natural' antipsychotic. We predicted that OxtÀ/À mice would be more susceptible to the PPI-disrupting doses of psychotomimetics.
Materials and methods

Subjects
Oxt þ / þ and À/À mice were generated and genotyped as previously described. 32 Mice were backcrossed 10 generations into a C57BL/6J background; 22 Oxt þ / þ mice (12 males and 10 females) and 18 OxtÀ/À mice (8 males and 10 females) were used as subjects. All subjects were 2-to 4-month-old littermates generated from heterozygous matings. At weaning, mice were housed, up to five per a cage, in same-sex sibling groups for the duration of testing. Food and water were available ad libitum and the animals were kept in a temperature and humidity controlled environment on a 12:12 light-dark cycle. All experiments were performed during the light phase of the light-dark cycle.
Drugs
Based on the literature, 33, 34 as well as pilot studies (data not shown), the following doses were selected: 10 mg kg À1 for Apo and Amp and 6 mg kg À1 for PCP. Amp and PCP were dissolved in 0.9% sterile saline and Apo in 0.9% saline with 0.1% ascorbic acid added. Amp and Apo were diluted to 1.5 mg ml À1 and PCP to 1.2 mg ml
À1
. Saline (0.9%) was injected as a control at the same volume as Apo and Amp. Fifteen minutes prior to testing, Apo, Amp and saline were administered intraperitoneally and PCP was administered subcutaneously.
Apparatus
Acoustic startle was measured using the whole body reflexive flinch in reaction to a startle noise. A single startle chamber was used for all animals (SR-LAB; San Diego Instruments, San Diego, CA, USA). 35 The chamber consisted of a small, nonrestrictive Plexiglas tube mounted on a platform inside a larger ventilated chamber. A loudspeaker within the chamber produced the background noise as well as all pulse tones. Vibrations of the animal, transduced by a piezoelectric unit attached to the bottom of the platform, were digitized and stored on a computer. A total of 65 readings were taken at 1 ms intervals and the average, rather than the peak, amplitude was used to determine the acoustic startle reflex. Prior to the start of the experiment, sound levels within the chamber were calibrated using a sound meter.
Procedure
Each test session consisted of a 5-min acclimation period followed by 60 trials. During both the acclimation and testing periods, the speaker produced a 65 dB background noise. Sessions consisted of no-stimulus trials, pulse-alone trials and prepulse þ pulse trials. During no-stimulus trails, no tone was presented. The pulse-alone trials consisted of a 40 ms, 120 dB pulse. The prepulse þ pulse trials consisted of three prepulse tones of 68 dB (3 dB above background), 71 dB (6 dB above background) and 77 dB (12 dB above background), each 20 ms long and presented 100 ms prior to the pulse tone. Each session began and ended with the presentation of five pulsealone trials. In between, each stimulus was presented in blocks of 5 for a total of 10 blocks, and within each block, the order of the stimuli presentation was randomized. An individual test session lasted approximately 25 min.
Study design
Prior to testing with drugs, as well as a saline control, each animal was tested for baseline PPI, which occurred without any injections. Following this baseline measurement, a repeated measures design was used with each animal receiving saline (0.9%), Amp, Apo and PCP in a counterbalanced order. To avoid any residual drug effects, there was a minimum of 3 days between each trial. Habituation of startle was calculated using the average responses to the first block (Pulse 1) and last block (Pulse 2) of the five pulse-alone trials and comparing them. Startle magnitude was calculated as the average response to all of the pulse-alone trials, excluding the first and last blocks of five pulse-alone trials. The PPI percentage was calculated using the following equation: (1-(startle amplitude of the prepulse þ pulse trial/ startle amplitude of the pulse-alone trial)) Â 100.
Statistics
Since we were interested in habituation of startle within each testing session, comparisons were made within drug treatment. To correct for multiple comparisons the a was adjusted to P < 0.013. As body weight could affect the startle amplitude, a repeated measures analysis of covariance (ANCOVA), with body weight run as a covariate was used to compare the main effects of the five pulse-alone trials at the beginning (Pulse 1) and at the end of testing (Pulse 2), as well as main effects of genotype and sex. The two pulse-alone trials were the within-subject repeated measures factor and genotype and sex the betweensubject factors.
Startle was compared using a repeated measures ANCOVA, with body weight run as a covariate, comparing the main effects of drug treatment, genotype and sex, as well as their interactions. Drug treatment was the within-subject repeated measures factor, and genotype and sex the between-subject factors.
Baseline PPI percentage was analyzed using a repeated measures analysis of variance (ANOVA) with main effects of genotype, sex and prepulse intensity as well as their interactions compared. Prepulse intensity was the within-subject repeated measures factor and genotype and sex the betweensubject factors. As there was no main effect of sex or any interactions, data from male and female mice were combined.
In the subsequent drug study, PPI percentage was analyzed using a repeated measures ANOVA to compare main effects of genotype, drug treatment, prepulse intensity and sex, as well as their interactions. Drug treatment and prepulse intensity were the within-subject factors, and genotype and sex the between-subject factors. For post hoc comparisons of drug treatments to saline treatment, a Dunnett's twosided multiple-comparison test was used. All other post hoc comparisons were made using a TukeyKramer multiple-comparison test. One OxtÀ/À male mouse was removed from statistical analysis because its PPI percentage for all three prepulse levels in the control treatment (saline), were greater than three standard deviations from the mean. Because there was no main effect of sex or any interactions, data from male and female mice were combined. Data in figures and tables are presented as means±s.e.m.
Results
Habituation of startle
For all treatments there were no main effects of drug, sex, genotype or any interactions. The results of saline treatment can be found in Figure 1a , Amp in Figure  1b , Apo in Figure 1c and PCP Figure 1d .
Startle
There were no main effects of drug treatment, sex genotype or any interactions. These data are summarized in Table 1 . Figure 1 There were no effects of saline (a), 10 mg kg À1 of amphetamine (b), 10 mg kg À1 of apomorphine (c) or 6 mg kg À1 of phencyclidine (d) on the habituation of the startle reflex in oxytocin wild-type (Oxt þ / þ ) and knockout (OxtÀ/À) male and female mice. Pulse 1 and Pulse 2 refer to the average responses to the 120 dB pulses administered during the first block and last block, respectively, of the test session. Data were analyzed using a repeated measures analysis of covariance with body weight as the covariate.
PPI percentage
Baseline. There were no genotypic differences in baseline PPI percentage, but there was the expected main effect of prepulse intensity (F (2, 82) = 75.66, P < 0.05), with increases in intensity resulting in increased PPI percentage (Figure 2 ).
Drug treatment.
There was a main effect of drug treatment (F (3, 468) = 11.44, P < 0.05) and prepulse intensity (F (2, 468) = 204.39, P < 0.05), but no main effect of genotype. Treatment with Amp, Apo and PCP resulted in impaired PPI compared to saline treatment (Dunnett's P < 0.05). There was also the expected prepulse intensity-dependent increase in PPI percentage across all groups (Tukey-Kramer P < 0.05). Most importantly, there was an interaction between drug and genotype (F (3, 468) = 4.89, P < 0.05). Specifically in OxtÀ/À mice, treatment with PCP resulted in impaired PPI compared to saline treatment in Oxt þ / þ mice (Tukey-Kramer P < 0.05). There were no significant interactions of Amp or Apo with genotype (Tukey-Kramer P > 0.05). The data are graphed by genotype with Figure 3a representing the data from Oxt þ / þ mice and Figure 3b that from OxtÀ/À mice.
Discussion
Our data suggest that glutamatergic functioning is altered in OxtÀ/À mice. The disrupted PPI observed following PCP treatment in OxtÀ/À mice demonstrates that sensorimotor gating, mediated via the glutamatergic system, is in some way impaired in these animals. These decreases in PPI in OxtÀ/À mice are not due to genotypic differences in startle magnitude caused by PCP treatment, as our PCP treatment did not affect startle. Our results are consistent with a study in rats demonstrating PCPinduced disruptions of PPI can be ameliorated by pretreatment with Oxt. 27 They also found that Oxt pretreatment reduced the effects of Amp, but not Apo, on disrupted PPI. 27 The lack of genotypic effect observed following treatment with Amp or Apo suggests that the dopaminergic system, involved in the regulation of PPI, is less affected, if not normal, in OxtÀ/À mice.
The hypothesis that hypofunctioning of the glutamatergic system plays a role in schizophrenia is based on evidence in humans that treatment with PCP, [36] [37] [38] as well as ketamine (another noncompetitive NMDA receptor antagonist), 39, 40 results in the production of schizophrenia-like symptoms in healthy controls. 41 With regard to PPI, specifically, the findings in healthy patients are mixed, with one study reporting disruption of 'PPI-like' auditory gating following treatment with ketamine, 42 some studies reporting no effects of ketamine on PPI, 43, 44 and others reporting enhancement of PPI. [45] [46] [47] However, it is clear that patients with schizophrenia do have altered PPI 1, 5, [48] [49] [50] and that in nonhuman primates 51, 52 and rodents, [53] [54] [55] [56] treatment with NMDA antagonists disrupts PPI. Why there are discrepancies in the effects of NMDA antagonists on PPI between clinical and preclinical studies remains unknown. Perhaps they are due to differences in experimental design, though it could Abbreviations: Amp, amphetamine; Apo, apomorphine; PCP, phencyclidine. There were no main effects of treatment or sex, or any interactions, on startle amplitude. Data were analyzed using a repeated measures analysis of covariance with body weight as the covariate. also reflect fundamental differences in the glutamatergic regulation of PPI in humans versus animals. While the link between altered sensorimotor gating and glutamate is relatively well established, that between Oxt and glutamate is more speculative. The widespread distribution of the Oxt [57] [58] [59] and NMDA receptors 60, 61 in the mouse, including within the CSPP circuitry, certainly affords many opportunities for interactions. Most research to date examining interactions between the Oxt and glutamatergic systems has focused on the hypothalamic magnocellular Oxt neurons where glutamatergic circuits synchronize the bursting activity of magnocellular Oxt neurons in organotypic cultures 62 and glutamate is responsible for the fast excitatory input into the magnocellular neurons. [63] [64] [65] [66] Dendritic release of Oxt can reduce glutamatergic excitatory synaptic transmission through presynaptic actions in these nuclei. 67 Also, in acutely dissected rat SON preparations, combined vasopressin and Oxt application inhibits glutamate release. 68 However, Oxt facilitates glutamatergic transmission in rat olfactory bulb neurons in culture. 69 We are not aware of similar studies within the CSPP, so future investigations on glutamatergic expression and transmission within the CSPP of OxtÀ/À mice seem warranted.
Whereas the hypofunctioning of the glutamatergic system may be the most parsimonious explanation for the PPI deficits observed in OxtÀ/À mice, other neurotransmitter systems have been linked with the effects of PCP, albeit not directly. For example, PCPdisrupted PPI can be blocked by treatment with the broad spectrum dopamine/serotonin/norepinephrine receptor antagonist, iloperidone, which also prevents the PPI-disrupting effects of Apo. 70 The disruption of PPI with PCP treatment could also reflect an effect at s 1 receptors as the s 1 receptor ligand MS-377 blocks the effects of PCP, but not Apo, on disrupted PPI in rats. 71 This receptor, with low affinity for PCP, has been suggested to facilitate NMDA transmission. 72 The contributions of these systems, as well as others, on PCP-disrupted PPI in the OxtÀ/À mice should be explored in future studies.
As noted above, chronic PCP abuse by humans can result in a psychosis that presents conditions similar to that of schizophrenia patients. In rodents, while the positive symptoms are difficult to assess, the negative symptoms of schizophrenia can be induced with PCP treatment. Specifically, chronic treatment with PCP results in behavioral changes that are consistent with the cognitive deficits found in schizophrenia patients. 73 In rats, treatment with Oxt can reverse the social deficits caused by chronic PCP treatment. 74 In addition, treatment with the atypical antipsychotic clozapine normalizes some of the negative symptoms of schizophrenia 75 and can enhance the release of Oxt from neurons of the central nervous system. 26 Consistent with the aforementioned effects, OxtÀ/À mice have significant deficits in some of their cognitive functioning. OxtÀ/À mice have impaired social memory. 76 Aggression is higher in male mice from OxtÀ/À mothers but the same, or possibly reduced, in male mice from heterozygous mothers. [77] [78] [79] In addition, female OxtÀ/À mice have more, and male mice less, anxiety-like behavior than Oxt þ / þ mice. 77, 80 Therefore, it may be that the deficits seen in PCP-disrupted PPI in OxtÀ/À mice are an extension of their overall deficits in cognitive functioning, perhaps reflecting a change in the glutamatergic system, beyond the CSPP.
In conclusion, the findings of this study have provided further evidence supporting the hypothesis that Oxt may act as a natural antipsychotic. It appears that the Oxt system interacts with the glutamate Figure 3 The effects of treatment with saline, 10 mg kg À1 of amphetamine, 10 mg kg À1 of apomorphine or 6 mg kg À1 of phencyclidine on the prepulse inhibition (PPI) of the startle reflex percentage in oxytocin wild-type (Oxt þ / þ ; a) and knockout (OxtÀ/À; b) mice. Data were analyzed using a repeated measures analysis of variance. There were main effects of drug treatment, but not genotype. Compared to saline, treatment with Amp, Apo and PCP all had an effect on PPI percentage and there was a prepulse intensitydependent increase in PPI percentage across all groups. There was an interaction between drug and genotype. Specifically, in OxtÀ/À mice, treatment with PCP resulted in impaired PPI compared to saline treatment in Oxt þ / þ mice. system; how this interaction is influencing PPI remains unknown. Further studies exploring the specific neural substrates as well as the interaction of Oxt with other neurotransmitter systems will be important in elucidating the role of Oxt in human psychiatric and neurological disorders.
